The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 353
- 试验地点
- 1
- 主要终点
- number of antihypertensive agents
研究概览
简要总结
Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 80 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •to be 80 years of age
- •with history of hypertension and/or on hypertensive drug(s)
排除标准
- •legal protection measure.
研究组 & 干预措施
control group
absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive
干预措施: Antihypertensive Agents (Drug)
mild neurocognitive disorder
MMSE from 21 to 26 inclusive
干预措施: Antihypertensive Agents (Drug)
moderate neurocognitive disorder
MMSE from 11 to 20 inclusive
干预措施: Antihypertensive Agents (Drug)
severe neurocognitive disorder
MMSE less than or equal to 10
干预措施: Antihypertensive Agents (Drug)
结局指标
主要结局
number of antihypertensive agents
时间窗: during inclusion
among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker
次要结局
- orthostatic hypotension(during inclusion)
- class of antihypertensive medications(during inclusion)
- systolic and diastolic blood pressure(during inclusion)
研究者
Pr Athanase BENETOS
principal investigator
Central Hospital, Nancy, France